Risk Factors of Kanbayashi et al for Hand-Foot Skin Reaction (HFSR) Associated with Sorafenib Therapy

 

Patient selection: therapy with sorafenib

 

The most important risk factors for HFSR were:

(1) high C-reactive protein (CRP)

(2) first 6 weeks of therapy

 

Other risk factors for HFSR:

(1) female gender

(2) ECOG 0 or 1 at the start of sorafenib therapy

(3) not receiving a proton pump inhibitor (PPI). Therapy with PPI increases the pH of gastric acid, which may reduce bioavailability of the drug.